Trastuzumab‐associated cardiotoxicity

摘要: Trastuzumab is a monoclonal antibody used for the treatment of metastatic breast carcinoma in women whose tumors overexpress HER2 protein. Cardiotoxicity has been reported to occur with trastuzumab when administered alone and combination antineoplastic agents, particularly anthracyclines. The risk cardiotoxicity be 4% monotherapy 27% an anthracycline cyclophosphamide, but author's knowledge severe outcomes, such as death or permanent disability, are uncommon. majority cardiac effects mild moderate, nonspecific, medically manageable. Signs symptoms similar those observed patients who develop anthracycline-induced cardiomyopathy include tachycardia, palpitations, exertional dyspnea, which may progress congestive heart failure. pathogenesis histologic changes responsible trastuzumab-associated currently under investigation. Unlike toxicity, toxicity usually responds standard discontinuation trastuzumab, there no evidence that dose related. Current methods early detection trastuzumab-treated anthracycline-treated patients. Cardiac function established at baseline monitored regularly during by physical examination measurement left ventricular ejection fraction. improve proper treatment, some able continue receive trastuzumab.